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Abstract
We have previously demonstrated that Lactobacillus reuteri CRL1098 soluble factors were able to reduce TNF-a production
by human peripheral blood mononuclear cells. The aims of this study were to determine whether L. reuteri CRL1098 soluble
factors were able to modulate in vitro the inflammatory response triggered by LPS in murine macrophages, to gain insight
into the molecular mechanisms involved in the immunoregulatory effect, and to evaluate in vivo its capacity to exert anti-
inflammatory actions in acute lung injury induced by LPS in mice. In vitro assays demonstrated that L. reuteri CRL1098
soluble factors significantly reduced the production of pro-inflammatory mediators (NO, COX-2, and Hsp70) and pro-
inflammatory cytokines (TNF-a, and IL-6) caused by the stimulation of macrophages with LPS. NF-kB and PI3K inhibition by
L. reuteri CRL1098 soluble factors contributed to these inhibitory effects. Inhibition of PI3K/Akt pathway and the diminished
expression of CD14 could be involved in the immunoregulatory effect. In addition, our in vivo data proved that the LPS-
induced secretion of the pro-inflammatory cytokines, inflammatory cells recruitment to the airways and inflammatory lung
tissue damage were reduced in L. reuteri CRL1098 soluble factors treated mice, providing a new way to reduce excessive
pulmonary inflammation.
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Introduction
The acute respiratory distress syndrome (ARDS) is a common
disease that follows acute lung injury (ALI). ALI/ARDS is an
important clinical syndrome of acute respiratory failure resulting
from diffuse inflammation of the lung parenchyma, whose
common clinical risk factors include sepsis and trauma. Pulmonary
inflammation and pulmonary edema are two of the most
important pathological findings in ALI/ARDS [1]. ALI/ARDS
are characterized by neutrophil accumulation in the lung and
apoptosis of the pulmonary epithelial cells, and leads to the
destruction of the pulmonary epithelium and impairment of its
barrier function [2,3].
Lipopolysaccharide (LPS) has been referred to be an important
risk factor of induced ALI and ARDS [1–4]. LPS is able to induce
the inflammatory response by activating numerous inflammatory
cells and result in acute lung injury. In fact, excessive inflammatory
reactions and, in particular, neutrophil and macrophage activation
have been implicated in ALI/ARDS pathogenesis [1–4]. Exper-
imental administration of LPS, both systemically and intranasally,
has been used to induce pulmonary inflammation in animal
models of ALI. Administration of LPS in experimental animals
causes the pathological condition of ongoing sepsis and concom-
itant ARDS-like lung injury, including neutrophil sequestration
and lung edema [5].
In clinical cases, ALI/ARDS is a major problem that has a high
mortality rate of 30–40% [4,5]. Over the past decades, a variety of
interventions and intensive care strategies have been used in
treating patients with ALI/ARDS. However, only supportive
treatments with lung protective ventilation and a fluid conservative
strategy have been shown to be beneficial in improving morbidity
and mortality [5]. Thus, novel therapeutic strategies are needed to
improve the outcome of this disease.
Several studies have demonstrated that probiotic lactic acid
bacteria (LAB) can exert their beneficial effect on the host through
their immunomudulatory activity. Although most research con-
cerning LAB-mediated immune modulation is focused on the
gastrointestinal tract, recent studies have centered on whether
these immunomudulatory probiotic LAB (immunobiotics) might
beneficially modulate the respiratory immune system [6].
Research from the last decade demonstrates that immunobiotic
LAB represent a promising resource for the modulation of
respiratory immunity to improve protection against infectious
and inflammatory respiratory diseases [7,8].
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Immunobiotics reported to exert their regulatory properties on
cells of the immune system, including monocytes and macrophag-
es, and to modulate the production of cytokines. A large number
of studies have shown that the communication between immuno-
biotic LAB and host cells is multifactorial and involves a complex
interaction between several receptors on the host cells that
recognize multiple effector molecules on bacteria [9]. Moreover,
most of these effector molecules have been found to be
components of the cell-wall or associated to cell surface. In
addition, during the last decade, a substantial body of scientific
evidence has accumulated suggesting that certain extracellular
components produced by probiotic LAB could be responsible for
some of their mechanisms of action. The bacterial components
that would be able to directly interact with the host mucosal cells
include exopolysaccharides, lipoteichoic acids and surface-associ-
ated and extracellular proteins [10,11]. In this regard, we
demonstrated previously that Lactobacillus reuteri CRL1098
soluble factors are able to reduce tumor necrosis factor (TNF)-a
production by human peripheral blood mononuclear cells (PBMC)
[12,13]. Considering the fact that numerous studies have shown
that reducing the levels of TNF-a through the use of anti-TNF-a
antibodies or soluble TNF receptors is a safe and efficacious
treatment for inflammatory diseases, we hypothesized that L.
reuteri CRL1098 soluble factors (LrS) could be used to modulate
inflammation in vivo.
The aims of this study were to determine whether LrS were able
to modulate in vitro the inflammatory response triggered by LPS
in murine macrophages, to gain insight into the molecular
mechanisms involved in the immunoregulatory effect, and to
evaluate in vivo its capacity to exert anti-inflammatory actions in
ALI induced by LPS in mice.
Results
LrS reduce the production of pro-inflammatory factors in
LPS-challenged macrophages
We first evaluated whether LrS were able to modulate the
production of pro-inflammatory mediators in RAW 264.7
macrophages. As shown in Figure 1 treatment of macrophages
with LrS significantly reduced TNF-a, but did not induce
significant changes in the production of interleukin (IL)-6, IL-10
and nitric oxide (NO). No modifications in the expression of cyclo-
oxygenase (COX)-2 or heat shock protein (Hsp)-70 were observed
after LrS treatment. We also evaluated the effect of LrS in LPS-
challenged RAW cells. Stimulation of cells with LPS significantly
increased all the pro-inflammatory factors studied. However, the
levels of IL-6, TNF-a, NO, COX-2, and Hsp-70 were significantly
lower in LPS-challenged RAW cells treated with LrS (Figure 1). In
addition, the levels of the immunoregulatory cytokine IL-10 were
studied. Incubation of RAW cells with LPS augmented the
production of IL-10; however the levels of that cytokine were
significantly higher in LPS-challenged cells treated with LrS
(Figure 1).
LrS modulate NF-kB, Akt/PI3K and ERK K pathways in
LPS-challenged macrophages
In order to analyze the signaling pathways involved in the effect
of LrS, RAW macrophages were incubated with LrS and, NF-kB,
Akt, and ERK K pathways were evaluated by immunofluores-
cence or Western blot assays. As shown in Figure 2A, treatment
with LPS or LrS increased the translocation of the p65 subunit of
NF-kB from the cytosol to the nucleus of RAW macrophages
indicating an activation of this pathway. Reduced translocation of
the p65 subunit into the nucleus was observed in LPS-challenged
RAW cells treated with LrS (Figure 2A). In addition, ERKK was
activated by the coincubation of LPS with LrS. Challenge with
LPS increased the phosphorylation of Akt indicating an activation
of Akt/PI3K pathway (Figure 2C). In addition, we observed that
levels of phosphorylated Akt were restored to control values in
LPS-challenged RAW cells treated with LrS (Figure 2C).
We next investigated the expression of CD14 that is one
important component of the receptor complex that detect LPS in
macrophages. Treatment of RAW cells with LrS did not modify
the expression of CD14 (Figure 2D). Stimulation of macrophages
with LPS significantly increased the levels of CD14 protein, while
LPS-challenged RAW cells treated with LrS showed significantly
lower levels of CD14 (Figure 2D).
LrS reduce apoptosis of LPS-challenged macrophages
To evaluate apoptosis we used Anexin V (AV) and propidium
iodide (PI) and determined the percentage of AV+ and AV+PI+
macrophages. As shown in Figure 3A, the percentage of both AV+
and AV+PI+ macrophages were significantly increased after the
challenge with LPS, however LPS-challenged RAW cells treated
with LrS showed values of AV+ and AV+PI+ cells that were lower
than those observed in LPS controls. We also studied the levels of
the pro-apoptotic protein Bax and anti-apoptotic factors Bcl-2 in
macrophages. LPS challenge significantly increased levels of Bax
in RAW cells while the levels of Bcl-2 were not modified
(Figure 3B). LrS-treated cells showed levels of Bcl-2 that were not
different from unchallenged control cells. Additionally, the levels
of the pro-apoptotic protein Bax in LPS-challenged RAW cells
treated with LrS were significantly lower than those observed in
LPS controls (Figure 3B).
Nasally administered LrS reduce lung injuries in LPS-
challenged mice
We then evaluate whether LrS were able to exert anti-
inflammatory activities in vivo. For this purpose we used a mice
model of ALI induced by LPS administration. In these experi-
ments mice were challenged intranasally with LPS with or without
the co-administration of LrS. In addition, a third group of mice
receiving LPS plus dexamethasone were used as controls for anti-
inflammatory effect (Figure 4). Albumin content, a measure to
quantitate increased permeability of the bronchoalveolar-capillar-
ity barrier, and lactate dehydrogenase (LDH) activity, an indicator
of general cytotoxicity, were determined in bronchoalveolar
lavages (BAL). Both biochemical markers of lung injury were
significantly increased after the challenge with LPS (Figure 4A and
B). Treatment with dexamethasone or LrS significantly reduced
the levels of albumin and LDH in BAL when compared to LPS
controls. However, values of both biochemical markers were
significantly lower in mice treated with LrS than those receiving
dexamethasone (Figure 4A and B).
Nasally administered LrS beneficially modulate
inflammatory response in LPS-challenged mice
Challenge with LPS increased the number of blood and BAL
leukocytes and neutrophils in all the experimental groups. Both
dexamethasone and LrS significantly reduced the number of
leukocytes and neutrophils in blood and in the respiratory tract
when administered with LPS (Figure 5A and B). As shown in
Figure 6A, stimulation with LPS induced significant increases in
the levels of blood and BAL TNF-a, and IL-10. Both dexameth-
asone and LrS reduced the levels of BAL TNF-a when compared
to LPS controls. Only mice receiving LrS showed values of blood
and BAL IL-10 that were significantly higher than LPS or LPS+
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dexamethasone mice (Figure 6A). Finally, we determined the
expression of TNF-a, IL-1b, IL-6, IL-8, GCSF, and IL-10 in lungs
by RT-PCR. Stimulation with LPS significantly increased the
expression levels of all the pro-inflammatory cytokines studied as
Figure 1. Effect of Lactobacillus reuteri CRL1098 soluble factors (LrS) on pro-inflammatory factors production by RAW 264.7
macrophages. RAW 264.7 cells were incubated in DMEM (control group) or DMEM with LrS (LrS group) for 4 hours. In a second set of experiments,
control (LPS group)- and LrS (LrS+LPS group)-stimulated RAW 264.7 cells were challenged with LPS for 20 hours. A) Tumor necrosis factor (TNF)-a,
interleukin (IL)-6, IL-10, and nitric oxide (NO) production were measured in culture supernatants. B) Cyclo-oxygenase (COX)-2 and heat shock protein
(Hsp)-70 expression levels were evaluated by Western Blot analyses. Data shown is a representative result of three independent experiments. Values
not sharing the same letter were significantly different (p value ,0.05).
doi:10.1371/journal.pone.0110027.g001
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well as IL-10 (Figure 6B). Both dexamethasone and LrS were able
to significantly reduce the levels of lung TNF-a, IL-1b, IL-6, IL-8,
and GCSF when compared to controls (Figure 6B). On the other
hand, only LrS treatment was able to improve levels of IL-10 when
compared to LPS controls (Figure 6B).
Discussion
Inflammation is an essential aspect of the host’s response to
invading pathogens to maintain a healthy state. However,
aberrant inflammation leads to the up-regulation of several pro-
inflammatory mediators including cytokines and enzymes. It was
described that inducible nitric oxide synthase (iNOS) and COX-2
are important mediators of inflammation [14,15]. Both iNOS and
COX-2 are highly expressed in macrophages in response to
inflammatory inducers like LPS, and are responsible for the
production of NO and prostaglandin E2 (PGE2), respectively.
Evidence indicates that the excessive release of NO by activated
macrophages, and the activation of COX-2 with the increased
conversion of arachidonic acid to PGE2; are associated with
cytotoxicity at the site of inflammation, and have been correlated
with the progression of inflammation-associated disorders [14,15].
In addition, it was recently showed in mouse macrophages, that
Hsp70 inhibition or knockdown prevented LPS-stimulated iNOS
protein expression. Moreover, the preventing effect of Hsp70
inhibition on iNOS gene transcription was confirmed in vivo in
endotoxemic mice [16]. The inflammatory response also activates
macrophages to produce pro-inflammatory cytokines, such as IL-
1b, IL-6, and TNF-a. The binding of TNF-a to surface receptors
activates multiple signal transduction pathways and induces a
secondary response by increasing the expression of several
inflammatory cytokines that contribute to the biological activity
of TNF-a [17]. Overproduction of TNF-a by macrophages has
been also linked to several inflammatory diseases including cancer,
sepsis, rheumatoid arthritis, and inflammatory bowel disease [17].
Thus, strategies to down-regulate the expression of these pro-
Figure 2. Effect of Lactobacillus reuteri CRL1098 soluble factors (LrS) on NF-kB, Akt, and ERK K pathways, and CD14 expression in
RAW 264.7 macrophages. RAW 264.7 cells were incubated in DMEM (control group) or DMEM with LrS (LrS group) for 4 hours. In a second set of
experiments, control (LPS group)- and LrS (LrS+LPS group)-stimulated RAW 264.7 cells were challenged with LPS for 20 hours. A) NF-kB pathway was
evaluated by p65 translocation using immunofluorescence. B) Akt and ERKK phosphorylation, and CD14 expression were analyzed by Western Blot.
Data shown is a representative result of three independent experiments. The bar graphs indicate the densitometry values of phosphorylated protein/
non-phosphorylated protein expressed as ratio of control. Values not sharing the same letter were significantly different (p value ,0.05).
doi:10.1371/journal.pone.0110027.g002
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inflammatory mediators during inflammatory processes are
considered as potential therapeutic tools to alleviate the progres-
sion of inflammatory diseases caused by the activation of
macrophages.
In the present study, we demonstrated that LrS reduced LPS-
induced NO production, and Hsp70 and COX-2 expressions in
RAW 264.7 macrophages. LrS also reduced LPS-induced
production of the pro-inflammatory cytokines, TNF-a and IL-6.
Furthermore, immunofluorescence results revealed that LrS
reduced the translocation of the p65 subunit of NF-kB from the
cytosol to the nucleus of RAW macrophages. NF-kB is required
for maximal transcription and production of inflammatory
mediators, and has been reported to play an important role in
the pathogenesis of lung inflammatory diseases [18]. Since
expression of pro-inflammatory mediators is tightly regulated at
a transcriptional level via NF-kB pathway, the modulation of NF-
kB pathway by LrS treatment could be a potential therapeutic
application in inflammatory diseases.
Although the actual molecular mechanisms underlying the
down-regulation of NF-kB activation and cytokine production by
Figure 3. Effect of Lactobacillus reuteri CRL1098 soluble factors (LrS) on RAW 264.7 cells apoptosis. RAW 264.7 cells were incubated in
DMEM (control group) or DMEM with LrS (LrS group) for 4 hours. In a second set of experiments, control (LPS group)- and LrS (LrS+LPS group)-
stimulated RAW 264.7 cells were challenged with LPS for 20 hours. A) Apoptosis was evaluated by flow cytometry using Anexin V (AV) and propidium
iodide (PI). AV+ and AV+PI+ macrophages were studied to evaluate early and late apoptosis respectively. B) Pro-apoptotic protein Bax, and anti-
apoptotic factor Bcl-2 expressions were analyzed by Western Blot. Data shown is a representative result of three independent experiments. Values
not sharing the same letter were significantly different (p value ,0.05).
doi:10.1371/journal.pone.0110027.g003
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Figure 4. Effect of Lactobacillus reuteri CRL1098 soluble factors (LrS) on the lung tissue damage induced by LPS in mice. Male 6-week-
old BALB/c mice were randomly allocated into three groups: control group, LrS-treated group, and dexamethasone group (Dexa+LPS). LrS or
dexamethasone were given to animals by the nasal route immediately after nasal LPS administration. (A) Albumin content in bronchoalveolar lavages
(BAL) was evaluated as a measure of increased permeability of the bronchoalveolar-capillarity barrier. (B) Lactate dehydrogenase (LDH) activity in BAL
was evaluated as an indicator of general cytotoxicity. The results represent data from three independent experiments. Values not sharing the same
letter were significantly different (p value ,0.05).
doi:10.1371/journal.pone.0110027.g004
Figure 5. Effect of Lactobacillus reuteri CRL1098 soluble factors (LrS) on blood and respiratory leukocytes after nasal challenge with
LPS. Male 6-week-old BALB/c mice were randomly allocated into three groups: control group, LrS-treated group, and dexamethasone group (Dexa+
LPS). LrS or dexamethasone were given to animals by the nasal route immediately after nasal LPS administration. (A) Numbers of leucocytes and
neutrophils in bronchoalveolar lavages (BAL). (B) Numbers of leucocytes and neutrophils, and myeloperoxidase (MPO) activity in blood. The results
represent data from three independent experiments. Values not sharing the same letter were significantly different (p value ,0.05).
doi:10.1371/journal.pone.0110027.g005
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LrS remain unclear, our previous and present data indicate that
LrS would exert its anti-inflammatory effect through the inhibition
of Akt/PI3K pathway.
Some studies on signaling pathways that induce anti-inflamma-
tory activity in RAW macrophages determined that the regulation
of iNOS, COX-2, and pro-inflammatory cytokine production
induced by LPS was mediated by the modulation of NF-kB
through the inhibition of PI3K/Akt or MAPKs (ERK, JNK, and
p38) pathways [19]. We demonstrated in this work an inhibition of
NF-kB translocation to the nucleus in LrS-treated macrophages
exposed to LPS as well as a reduction of Akt phosphorylation. In
addition, we reported that LrS significantly increased the
phosphorylation of ERK after the challenge with LPS, indicating
that LrS does not exert its immunoregulatory effect through the
inhibition of this MAPK. Morjaria et al [20] showed that
imidazoquinoxalines are able to reduce TNF-a production in
PBMC by activating p38 MAPK and inhibiting the PI3K/Akt
pathway. In addition, it has been recently reported that
polysaccharides found in medicinal plants are able to exert anti-
inflammatory effects in RAW macrophages. Treatment of RAW
cells with anti-inflammatory polysaccharides inhibited LPS-
induced NF-kB and PI3K/Akt phosphorylation, while they had
no effect on ERK, JNK, or p38 MAPKs [21]. Our present studies
indicated that LrS is able to modulate NF-kB and to inhibit PI3K/
Akt pathway, as described by other anti-inflammatory compounds
[20,21].
Figure 6. Effect of Lactobacillus reuteri CRL1098 soluble factors (LrS) on blood and respiratory cytokines after nasal challenge with
LPS. Male 6-week-old BALB/c mice were randomly allocated into three groups: control group, LrS-treated group, and dexamethasone group (Dexa+
LPS). LrS or dexamethasone were given to animals by the nasal route immediately after nasal LPS administration. (A) Blood and bronchoalveolar
lavages (BAL) TNF-a, and IL-10 levels were determined by ELISA. (B) TNF-a, IL-1b, IL-6, IL-8, GCSF, and IL-10 expressions in lungs were determined by
RT-PCR. The results represent data from three independent experiments. Values not sharing the same letter were significantly different (p value ,
0.05).
doi:10.1371/journal.pone.0110027.g006
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In addition, a number of molecules have been identified on
macrophages that are involved in LPS responsiveness. These
include TLR4, MD2 and CD14 [22]. Following its release from
dividing or damaged bacteria, LPS is sequestered by an LPS-
binding protein, which transports it to CD14 on the surface of
macrophages. Subsequently LPS is transferred to MD2, a soluble
protein that is associated with the extracellular domain of TLR4.
Activation of TLR4 initiates cell signaling cascades leading to
translocation of NF-kB into the nucleus and transcription of pro-
inflammatory genes [22]. It was demonstrated that reduction in
the expression of MD2 or CD14 significantly abolished the
response of macrophages to LPS challenge. It was showed in
alveolar macrophages that MD-2 siRNA reduces the transcription
and protein expression of MD-2 efficiently and, that the LPS-
induced secretion of the pro-inflammatory cytokines was reduced
in MD-2 silenced cells [23]. In addition, Lei et al. [24]
demonstrated that siRNA targeting CD14 inhibits TNF-a, MIP-
2, and IL-6 secretion and NO production from LPS-induced
RAW 264.7 cells. In line with these previous studies, we showed
here that treatment of RAW macrophages with LrS significantly
reduced the expression of CD14.
We also demonstrated that LrS is able to modify apoptosis of
macrophages. Several studies showed that different lactobacilli
strains may act as pro-apoptotic or anti-apoptotic effectors. For
example, probiotic Lactobacillus rhamnosus produced molecules
that promoted lymphocyte and THP-1 cells apoptosis [25]. In
contrast, pre-treatment of rat hepatocytes with Enterococcus lactis
IITRHR1 and Lactobacillus acidophilus MTCC447 inhibited the
translocation of pro-apoptotic protein (Bax) and enhanced anti-
apoptotic (Bcl-2) protein levels [26]. Our previous results
demonstrated that LrS decreased apoptosis in PBMC to a half
value compared to control cells [13]. The decreased apoptosis
observed in PBMC and RAW macrophages treated with LrS can
be the result of a combination of different pathways. Because of
ERK K is associated to some anti-apoptotic pathways [27] and
this kinase is activated in PBMC [13] and in RAW macrophages,
the decreased apoptosis observed in those cells could be a
consequence of the activation of ERKK. In addition, the balance
between anti-apoptotic and pro-apoptotic signal transduction
pathways regulates the final response of cells to different stimuli.
Our present data also suggest that LrS is able to modify the
balance of pro-apoptotic Bax and anti-apoptotic Bcl-2 factors. In
fact, LPS challenge significantly increased levels of Bax in
macrophages while LrS-treated cells showed lower levels of this
pro-apoptotic protein.
It has been showed that inhibition of pro-inflammatory cytokine
production, cellular apoptosis, and NF-kB activation after LPS
challenge is able to reduce lung injuries and improve survival rate
[28,29]. Therefore, we next aimed to evaluate in vivo the anti-
inflammatory capacities of LrS by using a mice model of ALI.
In the absence of infection, alveolar macrophages prevent
overreaction to inhaled antigen and maintain an immunologically
suppressive environment. However, following antigenic challenge,
macrophages can switch from protection into immunopathology.
Alveolar macrophages play an important role in LPS-induced lung
inflammation because of the early release of pro-inflammatory
cytokines in response to LPS drives a cascade of inflammatory
reactions. These activities can conduct to damage of lung
architecture, influx of immune cells to the airways, and consequent
impairment of gas exchange [30]. In ALI, pro-inflammatory
cytokines that originate from alveolar macrophages recruit and
activate neutrophils, which adhere to the affected capillary
endothelium and migrate into air spaces, leading to severe lung
injury [31]. Those changes were observed in our mice model of
ALI. LPS administration significantly increased the number of
BAL neutrophils and levels of lung TNF-a, IL-1b, IL-6, and IL-8.
Moreover, LPS significantly increased the levels of BAL LDH and
albumin indicating increased cytotoxicity and alterations of the
alveolar barrier. We also observed that the nasal treatment with
LrS was able to protect lungs from LPS-induced damage and that
this effect was related to the capacity of LrS to significantly reduce
the levels of TNF-a, IL-1b, IL-6, and IL-8 as well as the
recruitment of inflammatory cells into the lungs. Considering the
in vitro results in RAW cells, we can speculate that the treatment
with LrS is able to functionally modulate respiratory macrophages
to induce the anti-inflammatory effect. However, it should be
consider that several other cells including epithelial cells and
dendritic cells are also responsible of modulating immune
responses in the respiratory tract [6,7]. To evaluate in vivo the
effect of LrS in those cell populations is an interesting topic for
future research.
Surprisingly, the anti-inflammatory effects of LrS were compa-
rable to the one achieved by dexamethasone. On the contrary,
biomarkers of lung injury, albumin and LDH, were higher in
dexamethasone-treated mice when compared to those receiving
LrS. Therefore, the anti-inflammatory and protective effects of
LrS are not only related to the reduction of pro-inflammatory
factors but also to the increase of immunoregulatory cytokines as
well. In fact, our results showed that LrS significantly augmented
IL-10 levels in both LPS-challenged RAW cells and in BAL and
serum of LPS-treated mice. It is known that an adequate balance
of pro-inflammatory and anti-inflammatory factors is essential for
limiting the detrimental effects of inflammation on the lung tissue.
Several studies reported that IL-10 has an important protective
role in controlling immunopathology during respiratory infections
[32,33] and ALI [34,35]. Therefore, the induction of IL-10 by LrS
could be an essential component of its protective effect in ALI.
Conclusions
In vitro assays demonstrated that L. reuteri CRL1098 soluble
factors significantly reduced the production of pro-inflammatory
mediators (NO, COX-2, and Hsp70) and pro-inflammatory
cytokines (TNF-a, and IL-6) caused by the stimulation of
macrophages with LPS. NF-kB and PI3K inactivation by L.
reuteri CRL1098 soluble factors contributes to these inhibitory
effects. Inhibition of PI3K/Akt pathway and the diminished
expression of CD14 could be involved in the immunoregulatory
effect. In addition, our in vivo data proved that the LPS-induced
secretion of the pro-inflammatory cytokines, inflammatory cells
recruitment to the airways and inflammatory lung tissue damage
were reduced in LrS treated mice, providing a new way to reduce
strong pulmonary inflammation.
Materials and Methods
Bacteria cultures and supernatant obtaining
Lactobacillus reuteri CRL1098 (provided by the Culture
Collection of Centro de Referencia para Lactobacilos, CERELA.
Tucuma´n, Argentina) was grown in MRS (de Man, Rogosa and
Sharpe medium, Britania, Buenos Aires, Argentina) up to mid
logarithmic growth phase at 37uC (OD at 560 nm of approxi-
mately 0.50). The culture was centrifuged (8,000 g for 10 min),
washed with phosphate-buffered saline (PBS) and RPMI 1640
medium with phenol red (GIBCO cat. Nu 22400, Grand Island,
NY, USA), resuspended in RPMI 1640 medium (GIBCO, Grand
Island, NY, USA) and then propagated 4 h at 37uC, 5% CO2 in
agitating conditions (46107 CFU/ml). The culture was centri-
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fuged and cell-free supernatant was aseptically filtered using
0.22 mm pore size low protein binding cellulose acetate filters
(Millipore, Bedford, MA, USA). The cell-free supernatant (pH 7.2)
was used as recovered from the filtrates (non-diluted). The cell-free
supernatant (pH 7.2) was frozen at 220uC for 24 h prior to the
lyophilisation in a Lyovac GT2 lyophilizer (Leybold Cologne,
Germany). Prior to the experiments, lyophilized cell-free super-
natant was resuspended in medium.
RAW 264.7cells and treatment with L. reuteri CRL1098
supernatant
Mouse macrophage cell line RAW 264.7 was cultured in
DMEM supplemented with 10% fetal bovine serum (FBS),
100 IU/mL penicillin and 100 mg/mL streptomycin (DMEM-
FBS) and maintained at 37uC in a 5% CO2 humidified incubator.
Cells were seeded in 35 mm-dishes or 24-well culture plates,
lowed to adhere for 8 h at 37 uC in a humidified atmosphere of
5% CO2 prior to the addition of Lactobacillus reuteri supernatant
(LrS) resuspended in medium (at a sub-cytotoxic dilution) and
incubated for 4 h. Then, cultures were exposed to LPS from E.
coli serotype O26: B6 (Sigma, St. Louis, MO, USA) at a final
concentration of 15 mg/ml for 20 h. In all experiments, the cells
were grown to 80–90% confluence and cell viability was assessed
by the Trypan-blue assay (Sigma, St. Louis, MO, USA).
Measurement of extracellular cytokine assay
Cytokines concentration was measured in cell free supernatants
of RAW 264.7 cells using enzyme-linked immunosorbent assay kits
(ELISA Ready-Set- Go!eBioscience, San Diego, CA, USA),
including mouse TNF-a, IL-6, and IL-10.
Measurement of NO in the culture media
The NO concentrations in supernatants of RAW 264.7 cells
were determined by using Griess reagent (Promega Corporation,
Madison, WI, USA). At prechosen intervals, 50 ml aliquots of
medium were mixed with an equal volume of sulfanilamide
solution (1% sulfanilamide in 5% phosphoric acid) and allowed to
stand for 10 min at room temperature in the dark. Then, was
added 50 ml of NED solution (0.1% N-1-naphthylenediamine
dihydrochloride) and allowed to stand for 10 min at room
temperature in the dark. The absorbance was measured at
540 nm with a microplate reader (VERSAmax, Molecular
devices, Sunnyvale, CA, USA). Standard curve for sodium nitrite
was used to acquire the level of NO produced by treated
RAW264.7 cells.
Western Blot Analyses
Treated RAW 264.7 cells were washed twice with 10mM PBS
(pH 7.4) and then lysed with RIPA lysis buffer in the presence of
protease inhibitors. Total protein concentrations were quantified
using DC protein assay kit (Bio-Rad, Hercules, USA). Whole-cell
lysates (30 mg) were resolved by 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and electrotrans-
ferred to polyvinylidene fluoride (PVDF) membranes (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and probed with various
primary antibodies. Membranes were blocked in 5% (w/v)
albumin prior to incubation with the primary antibodies anti-
COX-2, anti-Hsp70, anti-ERKK, anti-p-ERKK, anti-Akt, anti-
p-Akt, anti-CD14, anti-Bcl-2, anti-Bax, and anti-a-Tubulin (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and a peroxidase
conjugated secondary antibody (anti-rabbit IgG or anti-mouse
IgG). Blots were detected by chemiluminescence (Bio-Rad,
Hercules, USA) using standard X-ray films (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). Intensity of individual bands was
quantified using Image J densitometry software, and expressed
relative to a-Tubulin signal, as a measure of protein relative
abundance in the different conditions.
Confocal Microscopy Analysis
RAW 264.7 cells were planted on the coverglass bottom dishes
into 35 mm-dishesand then treated as described above. At
prechosen intervals, RAW 264.7 cells were washed three times
with PBS. The cells were fixed with 2% paraformaldehyde for
30 min, permeabilized with 0.1% Triton X-100 for 15 min,
blocked with 2% BSA in PBS for 30 min, incubated with an anti-
p65 primary antibody at room temperature for 1 h, sequentially
incubated with an Alexa Fluor 546-conjugated secondary antibody
at room temperature for 1 h in the dark, and finally incubated
with TOPRO at room temperature for 5 min in the dark. Images
were obtained using a Leica TCS SP2 AOBS confocal laser
microscope.
Flow cytometric analysis of apoptosis
Apoptosis was detected by flow cytometry using a FITC AV
Apoptosis Detection Kit I (Becton Dickinson, San Jose, CA, USA).
Briefly, RAW 264.7 cells were harvested by centrifugation, washed
with cold PBS and resuspended in 1X Binding Buffer at a final
concentration of 16106 cells/ml. Five micro liters AV and PI were
added to 100 ml of the cell suspension (16105 cells) and incubated
15 min at room temperature in dark. 1X Binding Buffer (400 ml)
was added to each sample before flow cytometry analysis.
Unstained and AV or PI stained RAW 264.7 cells were used as
controls of labeling. The percentage of viable and apoptotic cells
was analyzed on a FACSCalibur flow cytometer (Becton
Dickinson, San Jose, CA, USA) using the DeNovo software FCS
Express V. 4 RUO. Viable cells were negatives to PI and AV.
Early apoptotic cells were positives to AV and negatives to PI. Late
apoptotic cells were positives to PI and AV.
Animals
The experimental protocols were approved by the Ethical
Committee of Animal Care from the Reference Centre for
Lactobacilli (CERELA-CONICET, Tucuman, Argentina) under
the protocol number LEF-2013-01 and all efforts were made to
minimize suffering. Male 6-week-old BALB/c mice were obtained
from the closed colony kept at CERELA (Chacabuco 145, San
Miguel de Tucuma´n, Argentina). They were housed in plastic
cages in a controlled atmosphere (2262uC temperature, 5562%
humidity) with a 12 h light/dark cycle. ALI was induced in the
mice by nasal administration of LPS from E. coli O55:B5 (8 mg/
kg). The animals were randomly allocated into three groups:
control group, LrS-treated group, and dexamethasone (2 mg/kg)
group. LrS or dexamethasone was given to animals by nasal
administration immediately after LPS administration. Samples
were obtained at different times post LPS administration.
Biochemical analyses in BAL
BAL samples were obtained according to the technique
described previously [36]. Briefly the trachea was exposed and
intubated with a catheter and 2 sequential lavages were performed
in each mouse by injecting 0.5 mL of sterile PBS. The sample of
fluid was centrifuged for 10 min at 9006g, the supernatant fluid
was frozen at 270uC for subsequent biochemical analyses.
Albumin content was determined to measure the increase of
permeability of the bronchoalveolar-capillarity barrier was deter-
mined colorimetrically based on albumin binding to bromocresol
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green (Wiener Lab, Rosario, Argentina). The results were
expressed as mg/L. LDH activity was determined as indicator of
general cytotoxicity was determined by measuring the formation
of a reduced form of nicotinamideadenine dinucleotide using
Wiener Lab reagents and procedures (Wiener Lab, Rosario,
Argentina). The results were expressed as U/L of BAL fluid [36].
Total and differential blood leucocyte counts
Blood samples were obtained by cardiac puncture from sodium
pentobarbital-anesthetized animals and were collected in tubes
containing EDTA as an anticoagulant. Total number of leucocytes
was determined with a hemocytometer. Differential cell counts
were performed by counting 200 cells in blood smears stained with
May Gru¨nwald Giemsa stain using a light microscope (100x), and
absolute cell numbers were calculated [36].
Cytokine concentrations in serum and BAL
TNF-a, and IL-10 concentrations in serum and BAL, were
measured with commercially available enzyme-linked immuno-
sorbent assay (ELISA) technique kits following the manufacturer’s
recommendations (R&D Systems, MN, USA).
Quantitative expression analysis by real-time PCR
We performed two-step real-time quantitative PCR to charac-
terize the expression of IL-8, GM-CSF, IL-10, IL-1b, TNF-a and
IL-6 mRNAs in lungs. Total RNA was isolated from each sample
using TRIzol reagent (Invitrogen). All cDNAs were synthesized
using a Quantitect reverse transcription (RT) kit (Qiagen, Tokyo,
Japan) according to the manufacturer’s recommendations. Real-
time quantitative PCR was carried out using a 7300 real-time
PCR system (Applied Biosystems, Warrington, United Kingdom)
and the Platinum SYBR green qPCR SuperMix uracil-DNA
glycosylase (UDG) with 6-carboxyl-X-rhodamine (ROX) (Invitro-
gen). Primers were described previously [37,38]. The PCR cycling
conditions were 2 min at 50uC, followed by 2 min at 95uC, and
then 40 cycles of 15 s at 95uC, 30 s at 60uC, and 30 s at 72uC.
The reaction mixtures contained 5 ul of sample cDNA and 15 ul
of master mix, which included the sense and antisense primers.
Expression of b-actin was used to normalize cDNA levels for
differences in total cDNA levels in the samples.
Statistical analyses
All assays were performed at least in triplicate and the results
were expressed as mean values with standard deviations. Statistical
analyses were performed using GraphPad Prism 6 software (La
Jolla, CA, USA). Comparisons were accomplished by ANOVA
general linear model followed by Tukey’s post-hoc test. Statisti-
cally significant differences were defined at a p value ,0.05.
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